<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has submitted a filing to BSE confirming that it does not qualify as a 'Large Corporate' under the SEBI circular dated November 26, 2018 and the related BSE circular dated April 11, 2019. These circulars relate to fund-raising norms for large entities issuing debt securities. The company has stated that it does not meet the thresholds specified in Para 2.2 of the SEBI circular, and therefore the additional borrowing and disclosure obligations applicable to large corporates do not apply to it. The letter is signed by Dr. K Koteswara Rao, Chairman and Managing Director, dated January 12, 2026.
This is a routine regulatory compliance filing with no material impact on shareholders. It simply means the company is below the size threshold that triggers stricter debt-raising rules meant for large entities, and therefore faces fewer compliance obligations in this regard.